• On 16 April 2026, Quest Diagnostics announced that City of Hope is using its Haystack MRD circulating-tumor DNA test in multi-year clinical trials for about 500 solid-tumor cancer patients across fourteen U.S. sites, aiming to detect minimal residual disease, monitor treatment response, and identify recurrence earlier than standard imaging.
• This collaboration highlights Quest’s growing role in advanced oncology diagnostics, using longitudinal ctDNA measurements to support more personalized cancer care decisions.
• We’ll now examine how the City of Hope Haystack MRD collaboration could influence Quest Diagnostics’ investment narrative around advanced diagnostics.

Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you need to believe it can steadily grow core lab volumes while expanding in higher value advanced testing, without letting costs or reimbursement pressures erode margins. The City of Hope Haystack MRD trials reinforce Quest’s push into oncology and data rich diagnostics, but do not materially change the most immediate swing factors, which remain pricing headwinds from public payers and execution on cost controls and automation.

The City of Hope collaboration fits alongside Quest’s recent work with Guardant Health to make the Shield blood based colorectal cancer screening test broadly accessible through its network. Together, these relationships underscore how Quest is positioning its infrastructure as a preferred platform for advanced cancer diagnostics, which ties directly into the catalyst of higher test complexity and data centric services potentially supporting mix and profitability if adoption is sustained.

Yet even as advanced oncology partnerships expand, investors should be aware that concentrated exposure to government reimbursement means...

Quest Diagnostics' narrative projects $12.7 billion revenue and $1.3 billion earnings by 2029. This requires 4.9% yearly revenue growth and an earnings increase of about $0.3 billion from $988.0 million today.

Uncover how Quest Diagnostics' forecasts yield a $218.50 fair value, a 12% upside to its current price.

Exploring Other Perspectives

The Simply Wall St Community’s 2 fair value estimates for Quest span roughly US$218 to about US$301 per share, underscoring how far apart individual views can be. Against that backdrop, the push into higher complexity oncology testing is an important piece of how some investors think about Quest’s longer term revenue mix and resilience, so it is worth weighing several perspectives before forming your own view.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth just $218.50!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.